Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women, AP said. Both groups saw health improvements in blood pressure, blood sugar and blood fat levels, too.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.